Envisagenics’ Collaboration with Biogen Inc.

Goodwin Procter LLP advised Envisagenics on the deal.

Envisagenics announced its collaboration with Biogen Inc. (Nasdaq: BIIB) to advance ribonucleic acid (RNA) splicing research within central nervous system (CNS) diseases.

Envisagenics is an artificial intelligence-driven biotechnology company that focuses on the discovery of novel RNA splicing variants that cause cancer and other genetic diseases. Its SpliceCore® discovery platform re-envisions the human genome with a validated exon-centric approach, combined with machine learning algorithms and high-performance computing. It is up to 250 times more likely to discover novel targets than gene-centric discovery tools. Using innovative technology and RNA analysis expertise, Envisagenics accelerates the development of highly specific therapeutics that modulate RNA splicing variants that drive pathogenesis of oncology, neurodegenerative, and metabolic disorders.

As part of the collaboration, Biogen will leverage SpliceCore® to define and understand the regulation of different RNA isoforms in CNS cell types.

The Goodwin team was led by Lily Wound (Picture), Melissa Paddock, Kristopher Brown, and Carson Zheng.


Involved fees earner: Kristopher Brown – Goodwin Procter; Melissa Paddock – Goodwin Procter; Lily Wound – Goodwin Procter; Carson Zheng – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Envisagenics;

Martina Bellini

Author: Martina Bellini